
BBNX Stock Forecast & Price Target
BBNX Analyst Ratings
Bulls say
Beta Bionics is a compelling investment opportunity due to their consistent beat and raise track record, solid Q1 results, increased guidance for the year, and positive outlook for the launch of their new patch pump, Mint, and Phase 2a feasibility trial for their Bihormonal initiative. Potential risks to our thesis include competition, regulatory processes, reimbursement rate cuts, and slower sales force ramp and pharmacy access expansion. However, with the potential to substantially improve the treatment of diabetes through their innovative products, Beta Bionics has a bright future ahead.
Bears say
Beta Bionics is a commercial-stage medical device company focused on developing and commercializing solutions to improve the health and quality of life for people with diabetes through its iLet Bionic Pancreas product. While the company saw solid results in their 1Q26 report, with higher revenue and gross margin, concerns remain about their cash burn rate and potential delays in the launch of their patch product. This, combined with the fact that the company is still in its early stages and has yet to achieve profitability, contribute to the analyst's negative outlook on the stock.
This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.
BBNX Analyst Forecast & Price Prediction
Start investing in BBNX
Order type
Buy in
Order amount
Est. shares
0 shares